Aspen Pharmacare Pty Limited Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Aspen Pharmacare Pty Limited Pharmaceutical Import Records from India — 5 Products, $4.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aspen Pharmacare Pty Limited — Pharmaceutical Importer Profile (2026) | 5 Products, $4.8M Trade | TransData Nexus

Aspen Pharmacare Pty Limited

Pharmaceutical Importer · Australia · Respiratory Focus · $4.8M Total Trade · DGFT Verified

Aspen Pharmacare Pty Limited is a pharmaceutical importer based in Australia with a total trade value of $4.8M across 5 products in 4 therapeutic categories. Based on 96 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Aspen Pharmacare Pty Limited sources from 1 verified Indian supplier, with Strides Pharma Science Limited accounting for 100.0% of imports.

Aspen Pharmacare Pty Limited — Import Portfolio & Supplier Network

Aspen Pharmacare Pty Limited import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Aspen Pharmacare Pty Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Strides Pharma Science Limited	$876.2K	23	100.0%

Aspen Pharmacare Pty Limited sources from 1 verified Indian supplier across 22 distinct formulations. The sourcing is highly concentrated — Strides Pharma Science Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Panafcortelone prednisolone tablets BP 25MG 154070	$50.0K	1
Panafcortelone prednisolone tablets BP 5MG 81800.00x 60	$50.0K	1
Dexmethsone 4 dexamethasone tablets 4MG[aspen] 75840.00 x	$50.0K	1
Panafcort prednisone tablets [5MG] 80130.00 x	$50.0K	1
Lithicarb-lithium carbonate tablets 250MG [film coated](17133.00x 200's	$50.0K	1
Lithicarb-lithium carbonate tablets 250MG [film coated](17234.00x 200's	$50.0K	1
Vancocin 125MG - vancomycin hydrochloride capsules [125MG] [hard gelatin] (3990.00 x x 2 x 10's)	$50.0K	1
Panafcortelone-prednisolone tablets BP 5MG (160540.00 x 60 tabs)	$50.0K	1
Panafcortelone prednisolone tablets BP 25MG (157280.00x 30 tabs)	$50.0K	1
Cortate 25 cortisone tablets [25MG] (8160.00x 60's)	$50.0K	1
Panafcort prednisone tablets [25MG] (52800.00x 30 tabs	$50.0K	1
Panafcortelone prednisolone tablets BP 25MG (159300.00x 30 tabs	$50.0K	1
Cortate 25 cortisone tablets 25MG 7930 x 60s	$48.0K	1
Cortate 25 cortisone tablets [25MG] (7690.00x 60's	$46.7K	1
Dexmethsone 4 dexamethasone tablets 4MG[aspen] 37920.00 x	$44.1K	1

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Prednisolone	Respiratory	$2.4M	48	1.2%	7
2	Prednisone	Respiratory	$1.3M	26	1.3%	6
3	Vancomycin	Antibiotics	$750.0K	15	0.8%	16
4	Ranitidine	Gastrointestinal	$196.2K	4	1.6%	12
5	Griseofulvin	Advanced Antifungals	$150.0K	3	0.4%	13

Aspen Pharmacare Pty Limited imports 5 pharmaceutical products across 4 categories into Australia totaling $4.8M.

Aspen Pharmacare Pty Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Aspen Pharmacare Pty Limited is a subsidiary of Aspen Pharmacare Holdings Limited, a multinational pharmaceutical company headquartered in uMhlanga, South Africa. Established in 1997, Aspen has grown to become the largest pharmaceutical company in Africa, with a significant presence in over 50 countries across Africa, the Middle East, the Americas, Europe, Asia, and Australasia.

In Australia, Aspen Pharmacare Pty Limited operates as a pharmaceutical importer and distributor, focusing on the procurement and supply of finished pharmaceutical formulations. The company plays a crucial role in enhancing the availability of essential medicines within the Australian healthcare system, ensuring that a diverse range of therapeutic products is accessible to meet the needs of patients and healthcare providers.

2Distribution Network

While specific details about Aspen Pharmacare Pty Limited's warehouse locations and logistics capabilities in Australia are not publicly disclosed, the company's extensive global operations suggest a well-established distribution network. Aspen's manufacturing facilities are strategically located in various countries, including South Africa, Germany, France, and the Netherlands, enabling efficient production and distribution of pharmaceutical products.

In Australia, Aspen's distribution network is likely designed to ensure timely and reliable delivery of pharmaceutical products across the country. The company's global manufacturing footprint supports its ability to source and supply a wide range of medicines, catering to the diverse needs of the Australian market.

3Industry Role

Aspen Pharmacare Pty Limited serves as a pharmaceutical importer and distributor within Australia's supply chain. By sourcing finished pharmaceutical formulations from various international suppliers, including India, Aspen enhances the availability of essential medicines in the Australian market. The company's role is pivotal in bridging the gap between global pharmaceutical manufacturers and the Australian healthcare system, ensuring that a diverse array of therapeutic products is accessible to meet patient needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Aspen Pharmacare Pty Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Aspen Pharmacare Pty Limited's sourcing strategy exhibits a high degree of concentration, with a total import value of $4.8 million USD from India over 96 shipments, encompassing five products across four therapeutic categories. The top five imported products—Prednisolone, Prednisone, Vancomycin, Ranitidine, and Griseofulvin—account for 100% of the company's imports from India. This indicates a strategic focus on specific high-demand medications, potentially leveraging favorable pricing and supply chain efficiencies.

The exclusive reliance on a single supplier, STRIDES PHARMA SCIENCE LIMITED, for all 96 shipments, suggests a stable and long-term partnership. However, this single-source dependency also poses risks, such as supply disruptions due to unforeseen events affecting the supplier. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

2Supply Chain Resilience

Aspen Pharmacare Pty Limited's supply chain resilience is closely tied to its exclusive partnership with STRIDES PHARMA SCIENCE LIMITED. While this relationship ensures consistency in product quality and supply, it also exposes Aspen to potential vulnerabilities if STRIDES encounters operational challenges or regulatory issues. The lack of publicly available information regarding backup suppliers and the diversity of formulations imported suggests limited contingency planning.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the regulation of therapeutic goods, including pharmaceuticals, is overseen by the Therapeutic Goods Administration (TGA), a division of the Department of Health. The TGA is responsible for ensuring that therapeutic goods meet appropriate standards for quality, safety, and efficacy before they can be supplied in Australia. (tga.gov.au)

The primary legislation governing the regulation of therapeutic goods is the Therapeutic Goods Act 1989, which establishes the framework for the inclusion of therapeutic goods in the Australian Register of Therapeutic Goods (ARTG). This Act outlines the requirements for the import, export, manufacture, and supply of therapeutic goods in Australia. (tga.gov.au)

2Import Licensing & GMP

To import therapeutic goods into Australia, companies must ensure that the products are included in the ARTG, unless exempt. The sponsor of the product is responsible for applying for and maintaining the ARTG entry. Additionally, imported therapeutic goods must comply with Good Manufacturing Practice (GMP) standards, which are internationally recognized and ensure that products are consistently produced and controlled to quality standards. (tga.gov.au)

Quality & Labeling

Aspen Pharmacare Pty Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Aspen Pharmacare Pty Limited's focus on importing specific therapeutic categories—Respiratory (77.1%), Antibiotics (15.6%), and Gastrointestinal (4.1%)—aligns with the company's strategic objective to address prevalent health conditions in Australia. The substantial importation of respiratory medications, including Prednisolone and Prednisone, suggests a targeted approach to meet the needs of patients with respiratory disorders. The inclusion of antibiotics and gastrointestinal products further indicates Aspen's commitment to providing a comprehensive range of essential medicines.

2Sourcing Profile

Aspen Pharmacare Pty Limited's sourcing strategy emphasizes the procurement of generic pharmaceutical formulations, primarily from India. This approach leverages India's robust pharmaceutical manufacturing capabilities and cost advantages, enabling Aspen to offer affordable medicines in the Australian market. The focus on finished pharmaceutical formulations, rather than active pharmaceutical ingredients (APIs) or bulk drugs, indicates a strategic decision to streamline operations and ensure product quality and consistency.

3Market Positioning

Seller's Guide — How to Become a Supplier to Aspen Pharmacare Pty Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Aspen Pharmacare Pty Limited, particularly if they can offer high-quality, cost-effective pharmaceutical formulations that align with Aspen's therapeutic focus areas. Aspen's current sourcing strategy, which relies exclusively on STRIDES PHARMA SCIENCE LIMITED, presents an opportunity for alternative suppliers to establish relationships and diversify Aspen's supplier base, thereby enhancing supply chain resilience.

2Requirements & Qualifications

Indian exporters seeking to supply Aspen Pharmacare Pty Limited must ensure that their products are included in the ARTG and comply with GMP standards recognized by the TGA. Additionally, products must meet the TGA's quality and labeling requirements, including batch testing, stability, and serialization mandates. Establishing a partnership with Aspen may also require demonstrating the ability to meet Aspen's specific product and supply chain standards.

3How to Approach

Frequently Asked Questions — Aspen Pharmacare Pty Limited

What products does Aspen Pharmacare Pty Limited import from India?

Aspen Pharmacare Pty Limited imports 5 pharmaceutical products across 4 categories. Top imports: Prednisolone ($2.4M), Prednisone ($1.3M), Vancomycin ($750.0K), Ranitidine ($196.2K), Griseofulvin ($150.0K).

Who supplies pharmaceuticals to Aspen Pharmacare Pty Limited from India?

Aspen Pharmacare Pty Limited sources from 1 verified Indian suppliers. The primary supplier is Strides Pharma Science Limited (100.0% of imports, $876.2K).

What is Aspen Pharmacare Pty Limited's total pharmaceutical import value?

Aspen Pharmacare Pty Limited's total pharmaceutical import value from India is $4.8M, based on 96 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Aspen Pharmacare Pty Limited focus on?

Aspen Pharmacare Pty Limited imports across 4 categories. The largest: Respiratory (77.1%), Antibiotics (15.6%), Gastrointestinal (4.1%).

Get Full Aspen Pharmacare Pty Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.